Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients
Clinical trial NCT07648940 · COMPLETED
Trial details
- NCT number
- NCT07648940
- Sponsor
- Zodiac Produtos Farmaceuticos S.A.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-13
- Primary completion
- 2023-06-22
- Enrollment
- 74
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.